US20180244624A1 - Novel isonitramine compound and composition containing same for preventing or treating metabolic diseases - Google Patents
Novel isonitramine compound and composition containing same for preventing or treating metabolic diseases Download PDFInfo
- Publication number
- US20180244624A1 US20180244624A1 US15/752,592 US201615752592A US2018244624A1 US 20180244624 A1 US20180244624 A1 US 20180244624A1 US 201615752592 A US201615752592 A US 201615752592A US 2018244624 A1 US2018244624 A1 US 2018244624A1
- Authority
- US
- United States
- Prior art keywords
- group
- isonitramine
- hydrogen atom
- allyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 208000030159 metabolic disease Diseases 0.000 title claims abstract description 27
- POCJOGNVFHPZNS-UHFFFAOYSA-N isonitramine Natural products OC1CCCCC11CNCCC1 POCJOGNVFHPZNS-UHFFFAOYSA-N 0.000 title abstract description 19
- -1 isonitramine compound Chemical class 0.000 title description 7
- 235000013402 health food Nutrition 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 208000008589 Obesity Diseases 0.000 claims abstract description 19
- 235000020824 obesity Nutrition 0.000 claims abstract description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 12
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 44
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 44
- 150000001721 carbon Chemical class 0.000 claims description 25
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 22
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 22
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 22
- 125000002252 acyl group Chemical group 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 22
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 125000005843 halogen group Chemical group 0.000 claims description 22
- 150000002367 halogens Chemical class 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical group CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 22
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 22
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 22
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 22
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 22
- 239000004480 active ingredient Substances 0.000 claims description 18
- 208000016097 disease of metabolism Diseases 0.000 claims description 16
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 206010022489 Insulin Resistance Diseases 0.000 claims description 6
- 201000001421 hyperglycemia Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 2
- 201000008980 hyperinsulinism Diseases 0.000 claims description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- POCJOGNVFHPZNS-NXEZZACHSA-N isonitramine Chemical compound O[C@@H]1CCCC[C@@]11CNCCC1 POCJOGNVFHPZNS-NXEZZACHSA-N 0.000 abstract description 89
- 230000002401 inhibitory effect Effects 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 20
- 210000001789 adipocyte Anatomy 0.000 abstract description 16
- 230000003914 insulin secretion Effects 0.000 abstract description 14
- 230000004069 differentiation Effects 0.000 abstract description 11
- 102000004190 Enzymes Human genes 0.000 abstract description 9
- 108090000790 Enzymes Proteins 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 210000000496 pancreas Anatomy 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 230000023852 carbohydrate metabolic process Effects 0.000 abstract description 4
- 235000021256 carbohydrate metabolism Nutrition 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 235000000346 sugar Nutrition 0.000 abstract description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 31
- 0 *C1=C([4*])C([5*])=C(CC(C)(C)C)C([1*])=C1[2*] Chemical compound *C1=C([4*])C([5*])=C(CC(C)(C)C)C([1*])=C1[2*] 0.000 description 24
- 239000000243 solution Substances 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 102000004877 Insulin Human genes 0.000 description 16
- 108090001061 Insulin Proteins 0.000 description 16
- 229940125396 insulin Drugs 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000008103 glucose Substances 0.000 description 13
- 241000252212 Danio rerio Species 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108010016731 PPAR gamma Proteins 0.000 description 6
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 6
- 102000004139 alpha-Amylases Human genes 0.000 description 6
- 108090000637 alpha-Amylases Proteins 0.000 description 6
- 229940024171 alpha-amylase Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 102000000536 PPAR gamma Human genes 0.000 description 5
- ZSVYBYMINXSGJD-NSHDSACASA-N [H][C@]1(OC)CCCCC12([H])CCCN(C)C2 Chemical compound [H][C@]1(OC)CCCCC12([H])CCCN(C)C2 ZSVYBYMINXSGJD-NSHDSACASA-N 0.000 description 5
- 229960002632 acarbose Drugs 0.000 description 5
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- LWFUFLREGJMOIZ-UHFFFAOYSA-N 3,5-dinitrosalicylic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O LWFUFLREGJMOIZ-UHFFFAOYSA-N 0.000 description 3
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 description 3
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 3
- 102000043296 Lipoprotein lipases Human genes 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- WQMJAXGYDHLCRT-UHFFFAOYSA-N [H]C12(CCCCC1=O)CCCN(C)C2=O Chemical compound [H]C12(CCCCC1=O)CCCN(C)C2=O WQMJAXGYDHLCRT-UHFFFAOYSA-N 0.000 description 3
- FBSDADSBWLRFKJ-JTQLQIEISA-N [H][C@]1(OC)CCCCC12([H])CCCN(C)C2=O Chemical compound [H][C@]1(OC)CCCCC12([H])CCCN(C)C2=O FBSDADSBWLRFKJ-JTQLQIEISA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 102000011690 Adiponectin Human genes 0.000 description 2
- 108010076365 Adiponectin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical compound CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 1
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 102000002356 Nectin Human genes 0.000 description 1
- 108060005251 Nectin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000021258 carbohydrate absorption Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000007673 developmental toxicity Effects 0.000 description 1
- 231100000415 developmental toxicity Toxicity 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000015707 frontal fibrosing alopecia Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 230000004121 glycogenesis Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000012528 insulin ELISA Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000000270 postfertilization Effects 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000008791 toxic response Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Definitions
- the present invention relates to a composition for preventing or treating a metabolic disease, the composition including a stereoisomer of isonitramine or a derivative thereof, or a racemic mixture of the stereoisomers.
- GTT glucose tolerance test
- adipocytes increase insulin resistance by inhibiting the insulin metabolism in muscles and liver.
- the most representative factor is free fatty acid (FFA), which is produced by hydrolysis of fatty acids in triglycerides stored in an adipose tissue.
- FFA free fatty acid
- TNF and leptin that are secreted from adipocytes are suggested to cause insulin resistance (Hotamisligil GS. et al., Tumor necrosis factor a, a key component of the obesity-diabetes link, Diabetes, 43, pp. 1271-1278, 1994).
- lipid is the main energy metabolism with lipid degradation and lipid synthesis that are both increased.
- the increase in lipid degradation and consequent increased use of FFAs are the most significant features of obesity, especially abdominal obesity. High correlation between lipid volume and lipid oxidation is observed, suggesting that the increase in lipid volume is considered as a cause of increased serum FFA and lipid oxidation.
- a pharmaceutical composition and a health food have excellent effects of treating metabolic diseases, each of which includes, as an active ingredient, a stereoisomer of isonitramine or a derivative thereof, or a racemic mixture of the stereoisomers.
- the present disclosure is aimed to provide a pharmaceutical composition and a health food for preventing or treating a metabolic disease, each of which includes, as an active ingredient, a stereoisomer of isonitramine or a derivative thereof, or a racemic mixture of the stereoisomers.
- X may be selected from the group consisting of hydrogen, a C 1 -C 10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
- R 1 to R 5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C 1 -C 3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- Y may be selected from the group consisting of a hydrogen atom, a C 1 -C 10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
- carbon atoms at the 6 th position and the 7 th position may each be a chiral center.
- R 1 to R 5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C 1 -C 3 alkyl group, a C 1 -C 3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- Y may be selected from the group consisting of a hydrogen atom, a C 1 -C 10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
- R 1 to R 5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C 1 -C 3 alkyl group, a C 1 -C 3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group; and
- X may be selected from the group consisting of a hydrogen atom, a C 1 -C 10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
- R 1 to R 5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C 1 -C 3 alkyl group, a C 1 -C 3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- Y may be selected from the group consisting of a hydrogen atom, a C 1 -C 10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
- FIG. 1 shows structural formulae of (+)-isonitramine stereoisomer ((+)-isonitramine (1)) according to an embodiment and Compounds 2 to 6 thereof.
- FIG. 2 shows an inhibitory effect of (+)-isonitramine (1) according to another embodiment on a fat content.
- FIG. 3 shows an inhibitory mechanism of (+)-isonitramine (1) of FIG. 2 on differentiation of an adipocyte.
- FIG. 4 is a bar graph showing an inhibitory effect of (+)-isonitramine (1) according to another embodiment or Compounds 2 to 6 on activity of a carbohydrate metabolism enzyme.
- FIG. 5 shows an effect of (+)-isonitramine (1) of FIG. 4 on protection of pancreas.
- FIG. 8 shows a promoting effect of (+)-isonitramine (1) according to another embodiment on secretion of insulin.
- FIG. 9 shows an inhibitory effect of (+)-isonitramine (1) of FIG. 8 on PEPCK.
- the present disclosure provides a pharmaceutical composition for preventing or treating a metabolic disease, the pharmaceutical composition including, as an active ingredient, a stereoisomer represented by Formula 1 or a racemic mixture thereof:
- X may be selected from the group consisting of a hydrogen atom, a C 1 -C 10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
- R 1 to R 5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C 1 -C 3 alkyl group, a C 1 -C 3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- carbon atoms at the 6 th position and the 7 th position may each be a chiral center.
- stereoisomer refers to a molecule that has the same molecular formula and sequence of constituent atoms, but differs in arrangement of these atoms in space. That is, the stereoisomer produced by chiral centers at the 6 th position and the 7 th position of Formula 1 may be a (6R, 7R), (6R, 7S), (6S, 7S), or (6S, 7R) type.
- racemic mixture refers a mixture of (+)- and ( ⁇ )-isomers at an equal amount, i.e., 50:50. Therefore, the racemic mixture may be a mixture of stereoisomers (6R, 7R) and (6S, 7S) of Formula 1 at a ratio of 50:50 or a mixture of stereoisomers (6R, 7S) and (6S, 7R) of Formula 1 at a ratio of 50:50.
- the present disclosure provides a health food for preventing or alleviating a metabolic disease, the health food including, as an active ingredient, a stereoisomer represented by Formula 1 or a racemic mixture thereof:
- X may be selected from the group consisting of a hydrogen atom, a C 1 -C 10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
- R 1 to R 5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C 1 -C 3 alkyl group, a C 1 -C 3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- Y may be selected from the group consisting of a hydrogen atom, a C 1 -C 10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
- R 1 to R 5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C 1 -C 3 alkyl group, a C 1 -C 3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group; and
- carbon atoms at the 6 th position and the 7 th position may each be a chiral center.
- the stereoisomer produced by chiral centers at the 6 th position and the 7 th position of Formula 1 may be a (6R, 7R), (6R, 7S), (6S, 7S), or (6S, 7R) type.
- racemic mixture may be a mixture in which the stereoisomers (6R, 7R) and (6S, 7S) of Formula 1 are mixed at a ratio of 50:50 or a mixture in which the stereoisomers (6R, 7S) and (6S, 7R) of Formula 1 are mixed at a ratio of 50:50.
- the present disclosure provides a pharmaceutical composition for preventing and treating a metabolic disease, the pharmaceutical composition including, as an active ingredient, a stereoisomer represented by Formula 2 or a racemic mixture thereof:
- X may be selected from the group consisting of a hydrogen atom, a C 1 -C 10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
- R 1 to R 5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C 1 -C 3 alkyl group, a C 1 -C 3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- Y may be selected from the group consisting of a hydrogen atom, a C 1 -C 10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
- R 1 to R 5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C 1 -C 3 alkyl group, a C 1 -C 3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group; and
- carbon atoms at the 6 th position and the 7 th position may each be a chiral center.
- the stereoisomer produced by chiral centers at the 6 th position and the 7 th position of Formula 2 may be a (6R, 7R), (6R, 7S), (6S, 7S), or (6S, 7R) type.
- racemic mixture may be a mixture in which the stereoisomers (6R, 7R) and (6S, 7S) of Formula 2 are mixed at a ratio of 50:50 or a mixture in which the stereoisomers (6R, 7S) and (6S, 7R) of Formula 2 are mixed at a ratio of 50:50.
- the present disclosure provides a health food for preventing or alleviating a metabolic disease, the health food including, as an active ingredient, a stereoisomer represented by Formula 2 or a racemic mixture thereof:
- X may be selected from the group consisting of a hydrogen atom, a C 1 -C 10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
- R 1 to R 5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C 1 -C 3 alkyl group, a C 1 -C 3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- Y may be selected from the group consisting of a hydrogen atom, a C 1 -C 10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
- R 1 to R 5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C 1 -C 3 alkyl group, a C 1 -C 3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group; and
- carbon atoms at the 6th position and the 7th position may each be a chiral center.
- the stereoisomer produced by chiral centers at the 6 th position and the 7 th position of Formula 2 may be a (6R, 7R), (6R, 7S), (6S, 7S), or (6S, 7R) type.
- racemic mixture may be a mixture in which the stereoisomers (6R, 7R) and (6S, 7S) of Formula 2 are mixed at a ratio of 50:50 or a mixture in which the stereoisomers (6R, 7S) and (6S, 7R) of Formula 2 are mixed at a ratio of 50:50.
- the present disclosure provides a pharmaceutical composition for preventing and treating a metabolic disease, the pharmaceutical composition including, as an active ingredient, a stereoisomer represented by Formula 3 or a racemic mixture thereof:
- X may be selected from the group consisting of a hydrogen atom, a C 1 -C 10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
- R 1 to R 5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C 1 -C 3 alkyl group, a C 1 -C 3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- Y may be selected from the group consisting of a hydrogen atom, a C 1 -C 10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
- R 1 to R 5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C 1 -C 3 alkyl group, a C 1 -C 3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group; and
- a carbon atom at the 6 th may be a chiral center.
- the stereoisomer produced by a chiral center at the 6 th position of Formula 3 may be a (R) or (S) type.
- racemic mixture may be a mixture in which the stereoisomers (R) and (S) of Formula 3 are mixed at a ratio of 50:50.
- the present disclosure provides a health food for preventing or alleviating a metabolic disease, the health food including, as an active ingredient, a stereoisomer represented by Formula 3 or a racemic mixture thereof:
- X may be selected from the group consisting of a hydrogen atom, a C 1 -C 10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
- R 1 to R 5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C 1 -C 3 alkyl group, a C 1 -C 3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- Y may be selected from the group consisting of a hydrogen atom, a C 1 -C 10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
- a carbon atom at the 6 th position may be a chiral center.
- the stereoisomer produced by a chiral center at the 6 th position of Formula 3 may be a (R) or (S) type.
- racemic mixture may be a mixture in which the stereoisomers (R) and (S) of Formula 3 are mixed at a ratio of 50:50.
- the metabolic disease may be selected from the group consisting of obesity, diabetes, hyperlipidemia, hypertriglyceridemia, liver disease, arteriosclerosis, stroke, myocardial infarction, cardiovascular disease, hyperglycemia, insulin resistance, and hyperinsulinemia, but is not limited thereto.
- the pharmaceutical composition may be provided in one or more formulations selected from the group consisting of gels, emulsions, injections, powders, granules, aerosols, pasts, percutaneous absorbers, and patches according to a conventional method, but is not limited thereto.
- the pharmaceutical composition may further include at least one additive selected from the group consisting of suitable carriers, excipients, disintegrants, sweeteners, coatings, swelling agents, lubricants, flavoring agents, antioxidants, buffers, bacteriostats, diluents, dispersants, surfactants, binders, and lubricants that are typically used in the preparation of the pharmaceutical composition.
- suitable carriers excipients, disintegrants, sweeteners, coatings, swelling agents, lubricants, flavoring agents, antioxidants, buffers, bacteriostats, diluents, dispersants, surfactants, binders, and lubricants that are typically used in the preparation of the pharmaceutical composition.
- examples of the carriers, exipients, and diluents may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythrytol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxylbenzoate, talc, magnesium stearate, mineral oil and the like.
- the solid formulations for oral administration may include tablet, pill, powder, granule, capsule and the like, and may be prepared by mixing the composition with at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin and the like.
- excipient such as starch, calcium carbonate, sucrose, lactose, gelatin and the like.
- the lubricants such as magnesium stearate, talc and the like may be used.
- the liquid formulations for oral administration may include suspension, solution, emulsion, syrup and the like.
- simple diluents including water, liquid paraffin and the like, various excipients, such as wetting agent, sweetening agent, flavoring agent, preserving agent and the like may be used.
- the formulations for parenteral administration may include sterile aqueous solution, non-aqueous solvent, suspending agent, emulsifying agent, freeze-drying agent, suppository and the like.
- suspending agent and non-aqueous solvent may include propylene glycol, polyethylene glycol, plant oil, such as olive oil, injectable ester, such as ethyl oleate, and the like.
- the base material for suppository may be witepsol, macrogol, tween 61, cacao oil, laurin oil, glycerol gelatin and the like.
- a desirable dose of the stereoisomer or the racemic mixture thereof may vary depending on the condition and body weight of a subject, the type and severity of diseases, the drug form, and the administration route and period, and may be appropriately selected by one of ordinary skill in the art.
- a daily dose may be in a range of about 0.01 mg/kg to about 200 mg/kg, for example, about 0.1 mg/kg to about 200 mg/kg, and for example, about 0.1 mg/kg to about 100 mg/kg.
- the administration may be carried out once a day, or divided into several times.
- the scope of the present disclosure is not limited thereto.
- subject as used herein may refer to a mammal including human, but is not limited thereto.
- the health food may be provided in the form of powders, granules, tablets, capsule, syrup, or beverage.
- the health food may be used together with other foods and food additives in addition to the stereoisomer or the racemic mixture thereof, which is used as the active ingredient, and may be suitably used according to a conventional method.
- the amount of the active ingredient may be appropriately determined according to the purpose of use, for example, prevention, health, or therapeutic treatment.
- the effective dose of the stereoisomer or the racemic mixture thereof included in the health food may be used in accordance with the effective dose of the pharmaceutical composition.
- the effective dose of the active ingredient when used for the purpose of health and hygiene, or for long-term consumption for health control purposes, the effective dose of the active ingredient may be less than the above ranges. Since the active ingredient has no problem in terms of safety, it is clear that the active ingredient can be used in an amount within the ranges described above.
- Types of the health food are not particularly limited, and examples thereof may include meat, sausage, bread, chocolate, candy, snack, cookie, pizza, ramen, other noodles, gum, dairy products including ice cream, various types of soups, beverages, teas, drinks, and alcoholic beverages, and a vitamin complex.
- the present inventors synthesized a stereoisomer of isonitramine of a derivative of isonitramine.
- 3T3-L1 mouse preadipocytes were cultured in a Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% newborn calf serum (Gibco BRL, N.Y., USA) and antibiotics (100 U/ml penicillin and 100 ⁇ g/ml streptomycin, Gibco BRL, N.Y., USA) in an incubator under humidification conditions of a temperature of 37° C. and 5% CO 2 .
- DMEM Dulbecco's modified Eagle's medium
- antibiotics 100 U/ml penicillin and 100 ⁇ g/ml streptomycin, Gibco BRL, N.Y., USA
- the cultured 3T3-L1 mouse cells were treated with 0.5 mM 1-methyl-3-isobutylxanthine purchased from Sigma (St. Louis, Mo.), 1 ⁇ M dexamethasone, 1 ⁇ g/mL insulin, and 10% fetal bovine serum (FBS, Gibco BRL), and then, cultured for 2 days to induce differentiation. After 2 days, the cultured medium was replaced with a fresh DMEM supplemented with 10% FBS and 1 ⁇ g/mL insulin. For the next 4 days, the cultured medium was replaced with a fresh DMEM supplemented with 10% FBS every day.
- FBS fetal bovine serum
- total cell RNA of the undifferentiated adipocytes and differentiated adipocytes was extracted by using Trizol (available from Invitrogen).
- RNA (4 ⁇ g) was reverse-transcribed into cDNA by using M-MLV reverse transcriptase (available from Promega). Accordingly, the expression of peroxisome proliferator-activated receptor ⁇ (PPAR ⁇ ), CCAAT/enhancer binding protein- ⁇ (C/EBP ⁇ ), adipocyte protein 2 (aP2), lipoprotein lipase (LPL), and adiponectin was each confirmed.
- PPAR ⁇ peroxisome proliferator-activated receptor ⁇
- C/EBP ⁇ CCAAT/enhancer binding protein- ⁇
- aP2 adipocyte protein 2
- LPL lipoprotein lipase
- variable number of cycles was used to identify the amplification occurred in the linear phase.
- ⁇ -actin was used as an internal control group.
- the PCR products were separated by using 2.0% agarose gel, followed by being visualized by RedSafe nucleic acid staining (available from Intron, Korea) and UV irradiation.
- the undifferentiated or differentiated cells were washed three times with phosphate-buffered saline (PBS), and then, fixed with 4% 4-formaldehyde (PFA) at room temperature for 1 hour. Afterwards, the resulting cells were washed three times with PBS, and stained with 0.5 ⁇ g/ml of nile red (available from Sigma, St. Louis, Mo.) for 10 minutes. Following the completion of the staining, the resulting cells were washed with PBS, and the nuclei thereof were stained again with 4′-6-diamidino-2-phenylindole, (DAPI, available from Invitrogen). Images were obtained by using a phase contrast microscope (Axiovert M200 microscope, Zeiss).
- the concentration of triglyceride in the cells was measured by using a triglyceride reagent purchased from Sigma and a free glycerol reagent.
- the adipocytes were differentiated for 8 days with (+)-isonitramine 1 at a concentration of 100 ⁇ M or 500 ⁇ M, in a 6-well plate.
- the cells were washed with PBS, and then, lysed with 100 ⁇ l of a lysis buffer. 20 ⁇ l of the lysate was mixed with 20 ⁇ l of the triglyceride reagent, followed by being cultured for 30 minutes at a temperature of 37° C. Afterwards, 30 ⁇ l of the cultured mixture was loaded to a 96-well plate, and 100 ⁇ l of the free glycerol reagent was added to the plate, followed by being cultured for 5 minutes at a temperature of 37° C.
- the absorbance of the cells was measured by using a spectrophotometer at a wavelength of 540 nm.
- (+)-isonitramine (1) which was synthesized according to Example 1, on fat accumulation and adipocyte differentiation, it was confirmed that (+)-isonitramine (1) inhibited the differentiation of the 3T3-L1 mouse preadipocytes into mature adipocytes as shown in FIG. 2A , and that (+)-isonitramine (1) decreased the concentration of triglyceride in a concentration-dependent manner as shown in FIG. 2B .
- the mRNA expression of each of PPAR ⁇ that are responsible for the differentiation of adipocytes and C/EBP ⁇ that promotes biosynthesis of fat and differentiation of adipocytes was inhibited without cytotoxicity, wherein PPAR ⁇ is known to induce adverse effects, such as obesity and fatty liver, when over-expressed.
- the mRNA expression of aP2, LPL, and adiponectin, which is regulated by PPAR ⁇ and C/EBP ⁇ as transcript factor was weakened.
- the isonitramine stereoisomer of the present disclosure had effects on the prevention or treatment of obesity related to fat accumulation.
- a glucose assay kit was purchased for use from Youngdong Company (Seoul, Korea).
- porcine ⁇ -amylase, yeast ⁇ -glucosidase, 3,5-dinitrosalicylic acid (DNS), p-nitrophenol glucoside (pNPG), rat intestinal acetone powder, sucrose, and maltose were purchased.
- Soluble starch was obtained from Samchun Chemical Company (Seoul, Korea), and Acarbose was purchased from Tokyo chemical industry Company (Tokyo, Japan).
- the mixtures were pre-cultured at a temperature of 37° C. for 10 minutes, and 25 ⁇ l of 0.5% starch solution was added thereto, followed by being cultured at a temperature of 37° C. for 10 minutes. Then, the mixtures were cultured again at a temperature of 100° C. for 5 minutes to stop the reaction, and the mixtures were cooled.
- a x indicates an absorbance value of a control group
- a 0 indicates an absorbance value of a test group upon treatment of isonitramine
- the mixtures were pre-cultured at a temperature of 37° C. for 10 minutes, and 25 ⁇ l of pNPG was added thereto, followed by being cultured at a temperature of 60° C. for 10 minutes. Then, 1N NaOH was added thereto to stop the reaction.
- the resulting solution in which a color reaction was induced was transferred to a 96-well plate, and absorbance thereof was measured at a wavelength of 405 nm by using a 96-well microplate reader.
- rat intestinal acetone powder 100 mg was added to 3 ml of 0.9% NaCl solution, and a homogenizing process was performed thereon for 5 minutes in the ice.
- the mixed solution was subjected to centrifugation at a speed of 12,000 rpm for 30 minutes, and then, the supernatant was removed therefrom and the precipitate was transferred to a 15 ml tube.
- a substrate for use as a substrate, 1 mM pNPG, 56 mM sucrose, and 5 mM maltose were dissolved in 0.1M PBS (pH 7.0). 50 ⁇ l of the substrate was added to the cultured mixtures, and cultured at a temperature of 37° C. for 5 minutes.
- reaction solution 5 ⁇ l was then mixed with 500 ⁇ l of glucose trinder kit solution, and cultured at a temperature of 37° C. for 5 minutes.
- the resulting solution in which a color reaction was induced was cultured at a temperature of 100° C. for 2 minutes to stop the reaction, and then, transferred to a 96-well plate. Then, absorbance thereof was measured at a wavelength of 570 nm.
- D-glucose was diluted with 0.1M PBS (pH 7.0) to various concentrations (0 to 480 mg/dL).
- glucose reference solution 5 ⁇ l was mixed with 500 ⁇ l of glucose trinder kit solution, and cultured at a temperature of 37° C. for 5 minutes.
- the resulting solution in which a color reaction was induced was cultured at a temperature of 100° C. for 2 minutes to stop the reaction, and then, transferred to a 96-well plate. Then, absorbance thereof was measured at a wavelength of 570 nm.
- 5-day-old zebrafish larvae ins:EGFP larvae were added to a 96-well plate, and reacted with (+)-isonitramine (1) of Example 1 at a temperature of 27° C. for 24 hours. Then, each larva was put to a fresh E3 solution, in which 500 ⁇ M alloxan (available from Sigma, St. Louis, Mo., USA) was added or not added, for 30 minutes.
- the pixel intensity of the pancreas was measured by using Image J software, as a percentage of the region of enhanced green fluorescent protein (EGFP), and statistically compared and recorded.
- EGFP enhanced green fluorescent protein
- the zebrafish was anesthetized by placing it in water at a temperature of 8° C. for 20 seconds.
- the zerafish was subjected to intraperitoneal injection of STZ or PBS three times (350 mg/kg) for a week. After the final injection, the zerafish was fed with commercial flake food (available from Tetrabits tropical flakes, Tetra, Germany) for 5 days.
- the zebrafish to which PBS was injected was fed with commercial flask food, and the zebrafish to which STZ was injected was fed with flake mixed with (+)-isonitramine (1) at various concentrations, for 1 hour. Afterwards, plasma blood of each zebrafish was enzymatically measured by using a glucose trinder kit.
- (+)-isonitramine (1) and Compound 2 to 6 synthesized according to Example 1 and as shown in FIG. 4 it was confirmed that (+)-isonitramine (1) and Compound 2 had selective inhibitory effects on metabolic enzymes essential for carbohydrate absorption, as compared with Compound 4 to 6.
- (+)-isonitramine (1) hardly inhibited ⁇ -amylase while inhibiting ⁇ -glucosidase, and there was little concern about side effects, such as abdominal distension and diarrhea of the existing drug, Acarbose.
- (+)-isonitramine (1) had no developmental toxicity and cardiovascular toxicity in the model of zerafish.
- (+)-isonitramine (1) exhibited effects on the reduction of blood glucose in a concentration-dependent manner.
- HIT-T15 cells a type of insulin cells, e.g., HIT-T15 cells, were obtained by the Korean Cell Line Back, and then, subcultured.
- the HIT-T15 cells were cultured in a RPMI1640 medium (available from invitrogen. Co, USA) supplemented with 10% fetal bovine serum (FBS, available from invitrogen. Co, New Zealand 10091-148), 100 mu/ml of penicillin, and 100 ⁇ g/ml of streptomycin, under humidification conditions of a temperature of 37° C. and 5% CO 2 .
- FBS fetal bovine serum
- Insulin secretion influenced by (+)-isonitramine was measured according to the recommended method using insulin ELISA kit (Cat.10-1113-01, available from Mercodia Company).
- the HIT-T15 cells were loaded to a 96-well plate at a concentration of 5 ⁇ 10 4 cells/well, and cultured until reaching 70% to 80% cell confluency in an incubator at a temperature of 37° C. in a CO 2 incubator. Then, the cells were pre-treated with 500 ⁇ M alloxan, which induces a pancreatic-specific toxic response, for 30 minutes. Afterwards, (+)-isonitramine was added to each well, and cultured for 24 hours.
- the culture solution was collected therefrom, and subjected to a centrifugation at a speed of about 15,000 rpm for 3 minutes.
- the cells were precipitated and the supernatant was accordingly prepared therefrom.
- 25 ⁇ l of the supernatant was added to each well of the ELISA kit, and 100 ⁇ l of enzyme conjugate solution was also added thereto and allowed to rest for 1 hour on a plate shaker, so as to induce an antigen-antibody reaction. After an hour, the supernatant was removed therefrom, and a washing buffer (350 ⁇ l) was used to wash non-specifically bound proteins or unbound proteins.
- a washing buffer 350 ⁇ l
- 200 ⁇ l of a substrate (TMB) was added and allowed for an enzymatic reaction at room temperature for 15 minutes.
- a zebrafish embryo is a model system that has been recently widely used in the fields of metabolic studies.
- the zebrafish embryo is widely used in the fields of diabetes and glucose metabolism research.
- a zerafish embryo was used to verify an effect of isonitramine on the expression of phosphoenolpyruvate carboxykinase (PEPCK), which is a key enzyme for regulating the first stage of gluconogenesis, and insulin.
- PEPCK phosphoenolpyruvate carboxykinase
- the zebrafish embryo underwent 96 hour post-fertilization (hpf) was exuviated, and then, treated with isonitramine for 48 hours.
- hpf 96 hour post-fertilization
- 100 mM cyclic AMP (cAMP) and 100 mM dexamethasone (DEX) were simultaneously treated with isonitramine, and then, cultured for 48 hours.
- TRIzol available from Invitrogen
- iScript cDNA Synthesis Kit available from Bio-Rad
- ⁇ -actin was used as an internal control group.
- the PCR products were separated by using 2.0% agarose gel, followed by being visualized by RedSafe nucleic acid staining (available from Intron, Korea) and UV irradiation.
- (+)-isonitramine a suitable amount of vitamin mixtures (70 ⁇ g of Vitamin A acetate, 1.0 mg of Vitamin E, 0.13 mg of Vitamin B1, 0.15 mg of Vitamin B2, 0.5 mg of Vitamin B6, 0.2 ⁇ g of Vitamin B12, 10 mg of Vitamin C, 10 ⁇ g of Biotin, 1.7 mg of nicotinamide, 50 ⁇ g of folic acid, and 0.5 mg of calcium pantothenate), and a suitable amount of inorganic mixtures (1.75 mg of ferrous sulfate, 0.82 mg of zinc oxide, 25.3 mg of magnesium carbonate, 15 mg of monobasic potassium phosphate, 55 mg of dibasic calcium phosphate, 90 mg of potassium citrate, 100 mg of calcium carbonate, and 24.8 mg of magnesium chloride) were mixed together, and granules thereof were prepared. Then, a health food containing the same was prepared according to a conventional method.
Abstract
Provided are a pharmaceutical composition for preventing or treating metabolic diseases and a health food for alleviating metabolic diseases, each of which the pharmaceutical composition and the health food includes, a stereoisomer of isonitramine or a derivative thereof, or a racemic mixture of the stereoisomers, wherein such a compound exhibits effects of inhibiting fat content or differentiation of an adipocyte, inhibiting activity of a carbohydrate metabolism enzyme, protecting pancreas, inhibiting blood sugar, and promoting insulin secretion, and thus can be favorably utilized in the treatment of metabolic diseases, such as obesity, diabetes, and hyperlipidemia.
Description
- The present invention relates to a composition for preventing or treating a metabolic disease, the composition including a stereoisomer of isonitramine or a derivative thereof, or a racemic mixture of the stereoisomers.
- As the standard of living improves with the development of the economy, the number of modern people who belong to obesity, which is the main cause of metabolic diseases, is rapidly increasing. In particular, it is recently reported that one third of Americans and 20% of children are obese patients in the United States. That is, these statistics do not simply mean the increase in the numbers, but also mean that health threats of modern people have increased.
- In this regard, the facts that obesity is associated with a high incidence of metabolic disorders of carbohydrates and diseases such as non-insulin dependent diabetes mellitus (NIDDM, type II diabetes), and that weight gain exacerbates existing diabetes have been reported. In addition, a number of studies have shown that obesity precedes impared glucose tolerance (IGT) and diabetes (see Carey V J. et al., Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women, The nurses' health study, Am J Epidemiol, 145, pp. 614-619, 1997). For example, Framingham's study found the frequent occurrence of IGT in obese people while most other studies found that obese people with IGT are high-risk people for the occurrence of NIDDM.
- According to a glucose tolerance test (GTT) that is one of methods of diagnosing diabetes and measures blood glucose before and after eating a certain amount of glucose, many obese patients show normal blood glucose response, but also show increased insulin resistance which causes insulin secretion response more frequently than normal people. Such insulin resistance is one of main symptoms of obesity and NIDDM, and is observed from the beginning of obesity.
- Although various hypotheses about the mechanism of decreased insulin metabolism in obesity have been proposed, but there is no definite mechanism yet. However, an insulin receptor related to the insulin metabolism, a glucose transporter, an enzymes related to glycogenesis and glycolysis have been observed to decrease in the insulin metabolism, and in this regard, the decrease in the insulin metabolism is understood as a secondary phenomenon caused by obesity (Golay A. et al., Obesity and NIDDMP, the retrograde regulation concept, Diabetes Rev, 5, pp. 69-82, 1997).
- Meanwhile, the recently published reports show that metabolic messengers or factors secreted from adipocytes increase insulin resistance by inhibiting the insulin metabolism in muscles and liver. Here, the most representative factor is free fatty acid (FFA), which is produced by hydrolysis of fatty acids in triglycerides stored in an adipose tissue. In addition, TNF and leptin that are secreted from adipocytes are suggested to cause insulin resistance (Hotamisligil GS. et al., Tumor necrosis factor a, a key component of the obesity-diabetes link, Diabetes, 43, pp. 1271-1278, 1994).
- In obesity, lipid is the main energy metabolism with lipid degradation and lipid synthesis that are both increased. The increase in lipid degradation and consequent increased use of FFAs are the most significant features of obesity, especially abdominal obesity. High correlation between lipid volume and lipid oxidation is observed, suggesting that the increase in lipid volume is considered as a cause of increased serum FFA and lipid oxidation.
- Furthermore, more than 70% of people with type II diabetes are obese, and the risk of developing other diseases such as hypertension, hyperlipidemia, and some cancers are reported to be increased from obesity.
- However, to date, there has not been developed a drug for the treatment of metabolic diseases, and attempts to treat metabolic diseases using drugs for treating diabetes, hyperlipidemia, and hypertension have limitations as medicines.
- Therefore, it is necessary to develop technologies that can effectively prevent and treat metabolic diseases by more efficiently controlling the induction mechanism of obesity and metabolic diseases induced by obesity.
- In this regard, the present inventors have completed the present disclosure by confirming that a pharmaceutical composition and a health food have excellent effects of treating metabolic diseases, each of which includes, as an active ingredient, a stereoisomer of isonitramine or a derivative thereof, or a racemic mixture of the stereoisomers.
- Therefore, the present disclosure is aimed to provide a pharmaceutical composition and a health food for preventing or treating a metabolic disease, each of which includes, as an active ingredient, a stereoisomer of isonitramine or a derivative thereof, or a racemic mixture of the stereoisomers.
- The achieve the objects of the present disclosure, the present disclosure provides a pharmaceutical composition or a health food for preventing or treating a metabolic disease, each of which includes, as an active ingredient, a stereoisomer represented by Formula 1 or a racemic mixture thereof:
- In Formula 1,
- X may be selected from the group consisting of hydrogen, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
- R1 to R5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- Y may be selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
- R1 to R5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group; and
- carbon atoms at the 6th position and the 7th position may each be a chiral center.
- In addition, the present disclosure provides a pharmaceutical composition or a health food for preventing or treating a metabolic disease, each of which includes, as an active ingredient, a stereoisomer represented by Formula 2 or a racemic mixture thereof.
- In Formula 2,
- X may be selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
- R1 to R5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- Y may be selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
- R1 to R5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group; and
- carbon atoms at the 6th position and the 7th position may each be a chiral center.
- In addition, the present disclosure provides a pharmaceutical composition or a health food for preventing or treating a metabolic disease, each of which includes, as an active ingredient, a stereoisomer represented by Formula 3 or a racemic mixture thereof.
- In Formula 3
- X may be selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
- R1 to R5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- Y may be selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
- R1 to R5 may may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group; and
- a carbon atom at the 6th position may be a chiral center.
- According to the present disclosure, a stereoisomer of isonitramine or a derivative thereof, or a racemic mixture of the stereoisomers exhibits effects of inhibiting a fat content or differentiation of an adipocyte, inhibiting activity of a carbohydrate metabolism enzyme, protecting pancreas, inhibiting blood sugar, and promoting insulin secretion, and thus, can be favorably used as a pharmaceutical composition or a health food for preventing or treating a metabolic disease.
-
FIG. 1 shows structural formulae of (+)-isonitramine stereoisomer ((+)-isonitramine (1)) according to an embodiment andCompounds 2 to 6 thereof. -
FIG. 2 shows an inhibitory effect of (+)-isonitramine (1) according to another embodiment on a fat content. -
FIG. 3 shows an inhibitory mechanism of (+)-isonitramine (1) ofFIG. 2 on differentiation of an adipocyte. -
FIG. 4 is a bar graph showing an inhibitory effect of (+)-isonitramine (1) according to another embodiment orCompounds 2 to 6 on activity of a carbohydrate metabolism enzyme. -
FIG. 5 shows an effect of (+)-isonitramine (1) ofFIG. 4 on protection of pancreas. -
FIG. 6 is a bar graph showing an inhibitory effect of (+)-isonitramine (1) ofFIG. 4 on blood sugar. -
FIG. 7 is a bar graph shows a promoting effect of (+)-isonitramine (1) according to an embodiment on secretion of insulin. -
FIG. 8 shows a promoting effect of (+)-isonitramine (1) according to another embodiment on secretion of insulin. -
FIG. 9 shows an inhibitory effect of (+)-isonitramine (1) ofFIG. 8 on PEPCK. - While synthesizing a stereoisomer of isonitramine or a derivative thereof and studying the synthesis, the inventors of the present disclosure completed the present disclosure by confirming that such synthetic products exhibit effects of inhibiting a fat content or differentiation of an adipocyte, inhibiting activity of a carbohydrate metabolism enzyme, protecting pancreas, inhibiting blood sugar, and promoting insulin secretion.
- Therefore, the present disclosure provides a pharmaceutical composition for preventing or treating a metabolic disease, the pharmaceutical composition including, as an active ingredient, a stereoisomer represented by Formula 1 or a racemic mixture thereof:
- In
Formula 1, - X may be selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
- R1 to R5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- Y may be selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
- R1 to R5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group; and
- carbon atoms at the 6th position and the 7th position may each be a chiral center.
- Here, the term ‘stereoisomer’ as used herein refers to a molecule that has the same molecular formula and sequence of constituent atoms, but differs in arrangement of these atoms in space. That is, the stereoisomer produced by chiral centers at the 6th position and the 7th position of
Formula 1 may be a (6R, 7R), (6R, 7S), (6S, 7S), or (6S, 7R) type. - The term ‘racemic mixture’ as used herein refers a mixture of (+)- and (−)-isomers at an equal amount, i.e., 50:50. Therefore, the racemic mixture may be a mixture of stereoisomers (6R, 7R) and (6S, 7S) of
Formula 1 at a ratio of 50:50 or a mixture of stereoisomers (6R, 7S) and (6S, 7R) ofFormula 1 at a ratio of 50:50. - In addition, the present disclosure provides a health food for preventing or alleviating a metabolic disease, the health food including, as an active ingredient, a stereoisomer represented by Formula 1 or a racemic mixture thereof:
- In
Formula 1, - X may be selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
- R1 to R5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- Y may be selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
- R1 to R5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group; and
- carbon atoms at the 6th position and the 7th position may each be a chiral center.
- That is, the stereoisomer produced by chiral centers at the 6th position and the 7th position of
Formula 1 may be a (6R, 7R), (6R, 7S), (6S, 7S), or (6S, 7R) type. - In addition, the racemic mixture may be a mixture in which the stereoisomers (6R, 7R) and (6S, 7S) of
Formula 1 are mixed at a ratio of 50:50 or a mixture in which the stereoisomers (6R, 7S) and (6S, 7R) ofFormula 1 are mixed at a ratio of 50:50. - Furthermore, the present disclosure provides a pharmaceutical composition for preventing and treating a metabolic disease, the pharmaceutical composition including, as an active ingredient, a stereoisomer represented by Formula 2 or a racemic mixture thereof:
- In
Formula 2, - X may be selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
- R1 to R5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- Y may be selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
- R1 to R5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group; and
- carbon atoms at the 6th position and the 7th position may each be a chiral center.
- That is, the stereoisomer produced by chiral centers at the 6th position and the 7th position of
Formula 2 may be a (6R, 7R), (6R, 7S), (6S, 7S), or (6S, 7R) type. - In addition, the racemic mixture may be a mixture in which the stereoisomers (6R, 7R) and (6S, 7S) of
Formula 2 are mixed at a ratio of 50:50 or a mixture in which the stereoisomers (6R, 7S) and (6S, 7R) ofFormula 2 are mixed at a ratio of 50:50. - In addition, the present disclosure provides a health food for preventing or alleviating a metabolic disease, the health food including, as an active ingredient, a stereoisomer represented by Formula 2 or a racemic mixture thereof:
- In
Formula 2, - X may be selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
- R1 to R5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- Y may be selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
- R1 to R5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group; and
- carbon atoms at the 6th position and the 7th position may each be a chiral center.
- That is, the stereoisomer produced by chiral centers at the 6th position and the 7th position of
Formula 2 may be a (6R, 7R), (6R, 7S), (6S, 7S), or (6S, 7R) type. - In addition, the racemic mixture may be a mixture in which the stereoisomers (6R, 7R) and (6S, 7S) of
Formula 2 are mixed at a ratio of 50:50 or a mixture in which the stereoisomers (6R, 7S) and (6S, 7R) ofFormula 2 are mixed at a ratio of 50:50. - Furthermore, the present disclosure provides a pharmaceutical composition for preventing and treating a metabolic disease, the pharmaceutical composition including, as an active ingredient, a stereoisomer represented by Formula 3 or a racemic mixture thereof:
- In
Formula 3, - X may be selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
- R1 to R5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- Y may be selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
- R1 to R5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group; and
- a carbon atom at the 6th may be a chiral center.
- That is, the stereoisomer produced by a chiral center at the 6th position of
Formula 3 may be a (R) or (S) type. - In addition, the racemic mixture may be a mixture in which the stereoisomers (R) and (S) of
Formula 3 are mixed at a ratio of 50:50. - In addition, the present disclosure provides a health food for preventing or alleviating a metabolic disease, the health food including, as an active ingredient, a stereoisomer represented by Formula 3 or a racemic mixture thereof:
- In
Formula 3, - X may be selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
- R1 to R5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
- Y may be selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
- R1 to R5 may each independently be a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group; and
- a carbon atom at the 6th position may be a chiral center.
- That is, the stereoisomer produced by a chiral center at the 6th position of
Formula 3 may be a (R) or (S) type. - In addition, the racemic mixture may be a mixture in which the stereoisomers (R) and (S) of
Formula 3 are mixed at a ratio of 50:50. - The metabolic disease may be selected from the group consisting of obesity, diabetes, hyperlipidemia, hypertriglyceridemia, liver disease, arteriosclerosis, stroke, myocardial infarction, cardiovascular disease, hyperglycemia, insulin resistance, and hyperinsulinemia, but is not limited thereto.
- The pharmaceutical composition may be provided in one or more formulations selected from the group consisting of gels, emulsions, injections, powders, granules, aerosols, pasts, percutaneous absorbers, and patches according to a conventional method, but is not limited thereto.
- In an embodiment, the pharmaceutical composition may further include at least one additive selected from the group consisting of suitable carriers, excipients, disintegrants, sweeteners, coatings, swelling agents, lubricants, flavoring agents, antioxidants, buffers, bacteriostats, diluents, dispersants, surfactants, binders, and lubricants that are typically used in the preparation of the pharmaceutical composition.
- In detail, examples of the carriers, exipients, and diluents may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythrytol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxylbenzoate, talc, magnesium stearate, mineral oil and the like. The solid formulations for oral administration may include tablet, pill, powder, granule, capsule and the like, and may be prepared by mixing the composition with at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin and the like. In addition, besides simple excipients, the lubricants, such as magnesium stearate, talc and the like may be used. The liquid formulations for oral administration may include suspension, solution, emulsion, syrup and the like. Besides simple diluents including water, liquid paraffin and the like, various excipients, such as wetting agent, sweetening agent, flavoring agent, preserving agent and the like may be used. The formulations for parenteral administration may include sterile aqueous solution, non-aqueous solvent, suspending agent, emulsifying agent, freeze-drying agent, suppository and the like. Examples of the suspending agent and non-aqueous solvent may include propylene glycol, polyethylene glycol, plant oil, such as olive oil, injectable ester, such as ethyl oleate, and the like. The base material for suppository may be witepsol, macrogol, tween 61, cacao oil, laurin oil, glycerol gelatin and the like.
- A desirable dose of the stereoisomer or the racemic mixture thereof may vary depending on the condition and body weight of a subject, the type and severity of diseases, the drug form, and the administration route and period, and may be appropriately selected by one of ordinary skill in the art. According to an embodiment, although not limited thereto, a daily dose may be in a range of about 0.01 mg/kg to about 200 mg/kg, for example, about 0.1 mg/kg to about 200 mg/kg, and for example, about 0.1 mg/kg to about 100 mg/kg. The administration may be carried out once a day, or divided into several times. Here, the scope of the present disclosure is not limited thereto.
- The term ‘subject’ as used herein may refer to a mammal including human, but is not limited thereto.
- The health food may be provided in the form of powders, granules, tablets, capsule, syrup, or beverage. The health food may be used together with other foods and food additives in addition to the stereoisomer or the racemic mixture thereof, which is used as the active ingredient, and may be suitably used according to a conventional method. Here, the amount of the active ingredient may be appropriately determined according to the purpose of use, for example, prevention, health, or therapeutic treatment.
- The effective dose of the stereoisomer or the racemic mixture thereof included in the health food may be used in accordance with the effective dose of the pharmaceutical composition. However, when used for the purpose of health and hygiene, or for long-term consumption for health control purposes, the effective dose of the active ingredient may be less than the above ranges. Since the active ingredient has no problem in terms of safety, it is clear that the active ingredient can be used in an amount within the ranges described above.
- Types of the health food are not particularly limited, and examples thereof may include meat, sausage, bread, chocolate, candy, snack, cookie, pizza, ramen, other noodles, gum, dairy products including ice cream, various types of soups, beverages, teas, drinks, and alcoholic beverages, and a vitamin complex.
- Hereinafter, to promote understanding of the present disclosure, reference has been made to Examples below. These Examples are provided so that the present disclosure will be thorough and complete, and will fully convey the concept of embodiments to one or ordinary skill in the art. In addition, these Examples are illustrated for convenience of explanation only, and thus, the scope of the present disclosure is not limited to Examples below.
- According to the methods disclosed in the documents in the related art by the present inventors, the present inventors synthesized a stereoisomer of isonitramine of a derivative of isonitramine.
- A stereoisomer of (+)-isonitramine ((+)-isonitramine 1) or
Compound 2 was synthesized according to the document already disclosed in the art Org. Lett. 2012, 14, 852-854). - In addition,
Compound 3 to 6 were synthesized according to the document already disclosed in the art (Adv. Synth. Catal. 2011, 353, 3313-3318.). - 1. Cell Culture and Differentiation
- 3T3-L1 mouse preadipocytes were cultured in a Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% newborn calf serum (Gibco BRL, N.Y., USA) and antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin, Gibco BRL, N.Y., USA) in an incubator under humidification conditions of a temperature of 37° C. and 5% CO2.
- Afterwards, the cultured 3T3-L1 mouse cells were treated with 0.5 mM 1-methyl-3-isobutylxanthine purchased from Sigma (St. Louis, Mo.), 1 μM dexamethasone, 1 μg/mL insulin, and 10% fetal bovine serum (FBS, Gibco BRL), and then, cultured for 2 days to induce differentiation. After 2 days, the cultured medium was replaced with a fresh DMEM supplemented with 10% FBS and 1 μg/mL insulin. For the next 4 days, the cultured medium was replaced with a fresh DMEM supplemented with 10% FBS every day.
- After 8 days, 90% or more of the cultured cells showed adipocyte phenotype.
- 2. Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
- According to the manufacturer's instructions, total cell RNA of the undifferentiated adipocytes and differentiated adipocytes was extracted by using Trizol (available from Invitrogen).
- The RNA (4 μg) was reverse-transcribed into cDNA by using M-MLV reverse transcriptase (available from Promega). Accordingly, the expression of peroxisome proliferator-activated receptor γ (PPARγ), CCAAT/enhancer binding protein-α (C/EBPα), adipocyte protein 2 (aP2), lipoprotein lipase (LPL), and adiponectin was each confirmed.
- Primers used herein are listed in Table 1 and were purchased from Bioneer.
-
TABLE 1 SEQ ID Name Direction Sequence NO: PPARγ Forward GTGATGGAAGACCACTCGCAT 1 Reverse ACCATTGGGTCAGCTCTTGTG 2 C/ EBPα Forward AGGTGCTGGAGTTGACCAGTG 3 Reverse CCGGAATCTCCTAGTCCTGGC 4 aP2 Forward AAGGTGAAGAGCATCATAACCCT 5 Reverse TCACGCCTTTCATAACACATTCC 6 LPL Forward GGGAGTTTGGCTCCAGAGTTT 7 Reverse TGTGTCTTCAGGGGTCCTTAG 8 Adipo- Forward TGTTCCTCTTAATCCTGCCCA 9 nectin Reverse CCAACCTGCACAAGTTCCCTT 10 β-actin Forward AGAGGGAAATCGTGCGTGAC 11 Reverse GGCCGTCAGGCAGCTCATAG 12 - The variable number of cycles was used to identify the amplification occurred in the linear phase.
- In the PCR amplification, β-actin was used as an internal control group. The PCR products were separated by using 2.0% agarose gel, followed by being visualized by RedSafe nucleic acid staining (available from Intron, Korea) and UV irradiation.
- 3. Nile Red staining
- The undifferentiated or differentiated cells were washed three times with phosphate-buffered saline (PBS), and then, fixed with 4% 4-formaldehyde (PFA) at room temperature for 1 hour. Afterwards, the resulting cells were washed three times with PBS, and stained with 0.5 μg/ml of nile red (available from Sigma, St. Louis, Mo.) for 10 minutes. Following the completion of the staining, the resulting cells were washed with PBS, and the nuclei thereof were stained again with 4′-6-diamidino-2-phenylindole, (DAPI, available from Invitrogen). Images were obtained by using a phase contrast microscope (Axiovert M200 microscope, Zeiss).
- 4. Analysis of Triglyceride Concentration
- The concentration of triglyceride in the cells was measured by using a triglyceride reagent purchased from Sigma and a free glycerol reagent.
- The adipocytes were differentiated for 8 days with (+)-
isonitramine 1 at a concentration of 100 μM or 500 μM, in a 6-well plate. - To analyze the concentration of triglyceride in the cells, the cells were washed with PBS, and then, lysed with 100 μl of a lysis buffer. 20 μl of the lysate was mixed with 20 μl of the triglyceride reagent, followed by being cultured for 30 minutes at a temperature of 37° C. Afterwards, 30 μl of the cultured mixture was loaded to a 96-well plate, and 100 μl of the free glycerol reagent was added to the plate, followed by being cultured for 5 minutes at a temperature of 37° C.
- Following the completion of the culturing, the absorbance of the cells was measured by using a spectrophotometer at a wavelength of 540 nm.
- 5. Experiment Results
- As a result of confirming the inhibitory effects of (+)-isonitramine (1), which was synthesized according to Example 1, on fat accumulation and adipocyte differentiation, it was confirmed that (+)-isonitramine (1) inhibited the differentiation of the 3T3-L1 mouse preadipocytes into mature adipocytes as shown in
FIG. 2A , and that (+)-isonitramine (1) decreased the concentration of triglyceride in a concentration-dependent manner as shown inFIG. 2B . - Furthermore, as shown in
FIG. 3 , the mRNA expression of each of PPARγ that are responsible for the differentiation of adipocytes and C/EBPα that promotes biosynthesis of fat and differentiation of adipocytes was inhibited without cytotoxicity, wherein PPARγ is known to induce adverse effects, such as obesity and fatty liver, when over-expressed. In addition, the mRNA expression of aP2, LPL, and adiponectin, which is regulated by PPARγ and C/EBPα as transcript factor, was weakened. - Therefore, it was confirmed that the isonitramine stereoisomer of the present disclosure had effects on the prevention or treatment of obesity related to fat accumulation.
- A glucose assay kit was purchased for use from Youngdong Company (Seoul, Korea). In addition, from Sigma Company, porcine α-amylase, yeast α-glucosidase, 3,5-dinitrosalicylic acid (DNS), p-nitrophenol glucoside (pNPG), rat intestinal acetone powder, sucrose, and maltose were purchased. Soluble starch was obtained from Samchun Chemical Company (Seoul, Korea), and Acarbose was purchased from Tokyo chemical industry Company (Tokyo, Japan).
- 1. Analysis of Inhibitory Effect of Porine α-amylase
- 5 μl of α-amylase (0.1 U/mL) was diluted with 50 mM phosphate buffer (pH 6.8), and the diluted solution was mixed with each of 100 μM (+)-isonitramine (1) or
Compound 2 to 6 of Example 1. In addition, as a positive control group, Acarbose was mixed at the same concentration with (+)-isonitramine (1). - The mixtures were pre-cultured at a temperature of 37° C. for 10 minutes, and 25 μl of 0.5% starch solution was added thereto, followed by being cultured at a temperature of 37° C. for 10 minutes. Then, the mixtures were cultured again at a temperature of 100° C. for 5 minutes to stop the reaction, and the mixtures were cooled.
- 25 μl of DNS was added to the cooled reaction solutions, and a color reaction was induced at a temperature of 100° C. for 5 minutes. The resulting solutions were cooled again. The solutions in which the color reaction was induced were transferred to a 96-well plate, and absorbance thereof was measured at a wavelength of 540 nm by using a 96-well microplate reader.
- Here, the inhibitory effect was calculated according to Equation 1:
-
Enzymatic inhibitory activity=(1−A x /A 0)×100% [Equation 1] - Ax indicates an absorbance value of a control group
- A0 indicates an absorbance value of a test group upon treatment of isonitramine
- 2. Analysis of Inhibitory Effect of Yeast α-amylase
- 5 μl of α-amylase (0.1 U/mL) was diluted with 50 mM sodium acetate buffer (pH 5.6), and the diluted solution was mixed with each of 100 μM (+)-isonitramine (1) or
Compound 2 to 6 of Example 1. In addition, as a positive control group, Acarbose was mixed at the same concentration with (+)-isonitramine (1). - The mixtures were pre-cultured at a temperature of 37° C. for 10 minutes, and 25 μl of pNPG was added thereto, followed by being cultured at a temperature of 60° C. for 10 minutes. Then, 1N NaOH was added thereto to stop the reaction.
- Afterwards, the resulting solution in which a color reaction was induced was transferred to a 96-well plate, and absorbance thereof was measured at a wavelength of 405 nm by using a 96-well microplate reader.
- 3. Analysis of Inhibitory Effect of Rat Intestinal Acetone Powder
- First, 100 mg of rat intestinal acetone powder was added to 3 ml of 0.9% NaCl solution, and a homogenizing process was performed thereon for 5 minutes in the ice. The mixed solution was subjected to centrifugation at a speed of 12,000 rpm for 30 minutes, and then, the supernatant was removed therefrom and the precipitate was transferred to a 15 ml tube.
- Then, 50 μl of enzyme solution was mixed with (+)-isonitramine (1), and as a positive control group, Acarbose was mixed at the same concentration with (+)-isonitramine (1). Each of the mixtures was cultured at a temperature of 37° C. for 5 minutes.
- Meanwhile, for use as a substrate, 1 mM pNPG, 56 mM sucrose, and 5 mM maltose were dissolved in 0.1M PBS (pH 7.0). 50 μl of the substrate was added to the cultured mixtures, and cultured at a temperature of 37° C. for 5 minutes.
- 5 μl of the reaction solution was then mixed with 500 μl of glucose trinder kit solution, and cultured at a temperature of 37° C. for 5 minutes. The resulting solution in which a color reaction was induced was cultured at a temperature of 100° C. for 2 minutes to stop the reaction, and then, transferred to a 96-well plate. Then, absorbance thereof was measured at a wavelength of 570 nm.
- To measure the glucose standard curve, D-glucose was diluted with 0.1M PBS (pH 7.0) to various concentrations (0 to 480 mg/dL).
- 5 μl of glucose reference solution was mixed with 500 μl of glucose trinder kit solution, and cultured at a temperature of 37° C. for 5 minutes. The resulting solution in which a color reaction was induced was cultured at a temperature of 100° C. for 2 minutes to stop the reaction, and then, transferred to a 96-well plate. Then, absorbance thereof was measured at a wavelength of 570 nm.
- 4. Measurement of Zebrafish Pancreatic Toxicity
- 5-day-old zebrafish larvae (ins:EGFP larvae) were added to a 96-well plate, and reacted with (+)-isonitramine (1) of Example 1 at a temperature of 27° C. for 24 hours. Then, each larva was put to a fresh E3 solution, in which 500 μM alloxan (available from Sigma, St. Louis, Mo., USA) was added or not added, for 30 minutes.
- After 30 minutes, all larvae were fixed with 4% para-formaldehyde (PFA) at room temperature for 50 minutes. A washing process using PBS was performed thereon, and fluorescence images of insulin showing expression of pancreatic islets were obtained by using a phase contrast microscope (Axiovert M200 microscope, Zeiss).
- Afterwards, the pixel intensity of the pancreas was measured by using Image J software, as a percentage of the region of enhanced green fluorescent protein (EGFP), and statistically compared and recorded.
- 5. Management of Postprandial Hyperglycemia in Diabetic-Inducible Zebrafish
- The zebrafish was anesthetized by placing it in water at a temperature of 8° C. for 20 seconds.
- For intraperitoneal injection, 350 mg/kg of a solution of 0.9% streptozocin (available from Sigma, St. Louis, Mo.) in 0.09% NaCl solution was injected with a syringe having 25 gauge needle (available from Trajan Scientific, Australia). Here, to a control group of zebrafish, the same amount of PBS was injected intraperitoneally. After the completion of the injection, the test and control groups of zebrafish were bread at a temperature of 24° C.
- The zerafish was subjected to intraperitoneal injection of STZ or PBS three times (350 mg/kg) for a week. After the final injection, the zerafish was fed with commercial flake food (available from Tetrabits tropical flakes, Tetra, Germany) for 5 days.
- After fasting for 24 hours, the zebrafish to which PBS was injected was fed with commercial flask food, and the zebrafish to which STZ was injected was fed with flake mixed with (+)-isonitramine (1) at various concentrations, for 1 hour. Afterwards, plasma blood of each zebrafish was enzymatically measured by using a glucose trinder kit.
- 6. Experiment Results
- As a result of confirming antidiabetic effects of (+)-isonitramine (1) and
Compound 2 to 6 synthesized according to Example 1 and as shown inFIG. 4 , it was confirmed that (+)-isonitramine (1) andCompound 2 had selective inhibitory effects on metabolic enzymes essential for carbohydrate absorption, as compared withCompound 4 to 6. In particular, it was also confirmed that (+)-isonitramine (1) hardly inhibited α-amylase while inhibiting α-glucosidase, and there was little concern about side effects, such as abdominal distension and diarrhea of the existing drug, Acarbose. - Furthermore, as shown in
FIG. 5 , it was confirmed that (+)-isonitramine (1) had no developmental toxicity and cardiovascular toxicity in the model of zerafish. As shown inFIG. 6 , it was also confirmed that (+)-isonitramine (1) exhibited effects on the reduction of blood glucose in a concentration-dependent manner. - 1. Cell Culture
- To identify effects of isonitramine derivatives on insulin secretion, a type of insulin cells, e.g., HIT-T15 cells, were obtained by the Korean Cell Line Back, and then, subcultured. In detail, the HIT-T15 cells were cultured in a RPMI1640 medium (available from invitrogen. Co, USA) supplemented with 10% fetal bovine serum (FBS, available from invitrogen. Co, New Zealand 10091-148), 100 mu/ml of penicillin, and 100 μg/ml of streptomycin, under humidification conditions of a temperature of 37° C. and 5% CO2.
- 2. Measurement of Insulin Secretion
- Insulin secretion influenced by (+)-isonitramine was measured according to the recommended method using insulin ELISA kit (Cat.10-1113-01, available from Mercodia Company). First, the HIT-T15 cells were loaded to a 96-well plate at a concentration of 5×104 cells/well, and cultured until reaching 70% to 80% cell confluency in an incubator at a temperature of 37° C. in a CO2 incubator. Then, the cells were pre-treated with 500 μM alloxan, which induces a pancreatic-specific toxic response, for 30 minutes. Afterwards, (+)-isonitramine was added to each well, and cultured for 24 hours. The culture solution was collected therefrom, and subjected to a centrifugation at a speed of about 15,000 rpm for 3 minutes. The cells were precipitated and the supernatant was accordingly prepared therefrom. 25 μl of the supernatant was added to each well of the ELISA kit, and 100 μl of enzyme conjugate solution was also added thereto and allowed to rest for 1 hour on a plate shaker, so as to induce an antigen-antibody reaction. After an hour, the supernatant was removed therefrom, and a washing buffer (350 μl) was used to wash non-specifically bound proteins or unbound proteins. Here, 200 μl of a substrate (TMB) was added and allowed for an enzymatic reaction at room temperature for 15 minutes. Then, 50 μl of a stop solution was added thereto to terminate the reaction. The changes resulted from the termination of the reaction were measured by using an ELISA-reader (VERSA max, micro-reader, MDS. Co, USA) at a wavelength of 450 nm.
- 3. Experiment Results
- The results showing the effects of (+)-isonitramine synthesized according to Example 1 on the insulin secretion are shown in
FIG. 7 . - Referring to
FIG. 7 , insulin secreted in a normal state was measured as 33.39±1.12 ng/mL (n=4), but it was confirmed that, when treated with alloxan, the insulin secretion was reduced to 18.92±0.43 ng/mL. That is, isonitramine showed an effect of increasing the insulin secretion in a concentration-dependent manner. - 1. Cell Culture
- A zebrafish embryo is a model system that has been recently widely used in the fields of metabolic studies. In particular, due to a metabolism in a manner very similar to that of the human body in terms of glucose regulation, the zebrafish embryo is widely used in the fields of diabetes and glucose metabolism research. Regarding the glucose metabolism, a zerafish embryo was used to verify an effect of isonitramine on the expression of phosphoenolpyruvate carboxykinase (PEPCK), which is a key enzyme for regulating the first stage of gluconogenesis, and insulin.
- In the experiment performed to verify the effect on the amount of insulin secretion, the zebrafish embryo underwent 96 hour post-fertilization (hpf) was exuviated, and then, treated with isonitramine for 48 hours. In the experiment performed to verify the effect on gluconeogenesis, 100 mM cyclic AMP (cAMP) and 100 mM dexamethasone (DEX) were simultaneously treated with isonitramine, and then, cultured for 48 hours.
- 2. Measurement of Insulin Secretion and Expression of PEPCK
- From the cultured embryo above, TRIzol (available from Invitrogen) was used to isolate mRNA, and the isolated RNA was synthesized to cDNA by using iScript cDNA Synthesis Kit (available from Bio-Rad). Afterwards, to amplify the cDNA, primers listed in Table 2 were used, wherein each primer was purchased from Bioneer.
-
TABLE 2 Name Direction Sequence SEQ ID NO: zf PEPCK Forward GAGAATTCTCACACACAC 13 ACACGTGAGCAGTA Reverse GTAAAAGCTTTCCGCCATAACATCTCCAGC 14 AGAA zf prepro- Forward AGTGTAAGCACTAACCCAGGCACA 15 insulin Reverse TGCAAAGTCAGCCACCTCAGTTTC 16 (insa) zf β-actin Forward CGAGCAGGAGATGGGAACC 17 Reverse CAACGGAAACGCTCATTGC 18 - In the PCR amplification, β-actin was used as an internal control group. The PCR products were separated by using 2.0% agarose gel, followed by being visualized by RedSafe nucleic acid staining (available from Intron, Korea) and UV irradiation.
- 3. Experiment Results
- The results showing the effects of (+)-isonitramine synthesized according to Example 1 on the insulin secretion and the expression of PEPCK are shown in
FIGS. 8 and 9 . - Referring to
FIG. 8 , as the concentration of isonitramine increased, the expression of insulin also increased. Referring toFIG. 9 , the inhibitory effect of isonitramine on the expression of PEPCK was significantly increased in proportion to the concentration of isonitramine. - That is, taking the results of Examples 4 and Example 5 together, it was confirmed that isonitramine and a pharmaceutical composition and a health food, which include isonitramine, promoted the expression insulin and inhibited gluconeogenesis at the same time, thereby exhibiting effects of reducing blood glucose.
- Hereinafter, Preparation Examples of a composition including the isonitramine stereoisomer of the present disclosure or a racemic mixture of the isonitramine stereoisomers will be described. However, the present disclosure is not intended to be limited thereto, but is specifically described as below.
- 20 mg of (+)-isonitramine, 100 mg of lactose, and 10 mg of talc were mixed together, and powders thereof were prepared by packing the mixture in an airtight bag.
- 1 mg of (+)-isonitramine, 100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate were mixed together, and tablets thereof were prepared by a tabletting process according to a conventional method.
- 10 mg of (+)-isonitramine, 100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate were mixed together, and capsules thereof were prepared by a capsulating process according to a conventional method.
- 10 mg of (+)-isonitramine, a suitable amount of sterilized and distilled water for injection, and a suitable amount of pH adjuster were mixed together, and injections containing the above-described ingredient contents per ampoule (2 ml) according to a conventional method of preparing injections.
- 10 mg of (+)-isonitramine, 250 mg of PEG-4000, 650 mg of PEG-400, 10 mg of white vaseline, 1.44 mg of methyl para-hydroxybenzoate, 0.18 mg of propyl para-hydroxybenzoate, and the remaining amount of purified water were mixed together, and an ointment thereof was prepared according to a conventional method of preparing an ointment.
- 1 mg of (+)-isonitramine, a suitable amount of vitamin mixtures (70 μg of Vitamin A acetate, 1.0 mg of Vitamin E, 0.13 mg of Vitamin B1, 0.15 mg of Vitamin B2, 0.5 mg of Vitamin B6, 0.2 μg of Vitamin B12, 10 mg of Vitamin C, 10 μg of Biotin, 1.7 mg of nicotinamide, 50 μg of folic acid, and 0.5 mg of calcium pantothenate), and a suitable amount of inorganic mixtures (1.75 mg of ferrous sulfate, 0.82 mg of zinc oxide, 25.3 mg of magnesium carbonate, 15 mg of monobasic potassium phosphate, 55 mg of dibasic calcium phosphate, 90 mg of potassium citrate, 100 mg of calcium carbonate, and 24.8 mg of magnesium chloride) were mixed together, and granules thereof were prepared. Then, a health food containing the same was prepared according to a conventional method.
- 1 mg of (+)-isonitramine, 1,000 mg of citric acid, 100 g of oilgosaccharide, 2 g of pulm concentrate, 1 g of taurine, and purified water were prepared to make a total of 900 ml, and the above ingredients were mixed according to a conventional method of preparing health drink. The mixture was stirred and heated at a temperature of 85° C. for about 1 hour, and then, the resulting solution was filtered. The filtrate was put in a sterilized 2 L container, and the container was then sealed and sterilized, and referigerated.
- While the present disclosure has been particularly shown and described with reference to specific embodiments thereof, one of ordinary skill in the art will readily appreciate that the embodiments provided herein may be embodied in many different forms and should not be construed as being limited to the embodiments set forth herein. Therefore, the substantial scope of the present disclosure will be defined by the appended claims and equivalents thereof.
Claims (4)
1. A pharmaceutical composition for preventing or treating a metabolic disease, the pharmaceutical composition comprising, as an active ingredient, a stereoisomer represented by Formula 1 or a racemic mixture thereof:
wherein, in Formula 1,
X is selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
R1 to R5 are each independently a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
Y is selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
R1 to R5 are each independently a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group; and
carbon atoms at the 6th position and the 7th position are each a chiral center.
2. The pharmaceutical composition of claim 1 , wherein the metabolic disease is selected from the group consisting of obesity, diabetes, hyperlipidemia, hypertriglyceridemia, liver disease, arteriosclerosis, stroke, myocardial infarction, cardiovascular disease, hyperglycemia, insulin resistance, and hyperinsulinemia.
3. A health food for preventing or treating a metabolic disease, the health food comprising, as an active ingredient, a stereoisomer represented by Formula 1 or a racemic mixture thereof:
wherein, in Formula 1,
X is selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when X is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when X is
R1 to R5 are each independently a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group;
Y is selected from the group consisting of a hydrogen atom, a C1-C10 alkyl group, an acyl group, an allyl group, and a benzyl group, wherein, when Y is an allyl group, one or more halogen may be substituted for the unsaturated carbon, or when Y is
R1 to R5 are each independently a hydrogen atom, a nitro group, a halogen atom, a cyano group, a hydroxyl group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, a vinyl group, an aryl group, a phenoxy group, or a benzoxy group; and
carbon atoms at the 6th position and the 7th position are each a chiral center.
4-9. (canceled)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150115504 | 2015-08-17 | ||
KR10-2015-0115504 | 2015-08-17 | ||
KR10-2016-0104145 | 2016-08-17 | ||
KR1020160104145A KR101799793B1 (en) | 2015-08-17 | 2016-08-17 | Novel Isonitramine Compound and Composition for Preventing or Treating Metabolic Disease Comprising the Same |
PCT/KR2016/009036 WO2017030367A1 (en) | 2015-08-17 | 2016-08-17 | Novel isonitramine compound and composition containing same for preventing or treating metabolic diseases |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/009036 A-371-Of-International WO2017030367A1 (en) | 2015-08-17 | 2016-08-17 | Novel isonitramine compound and composition containing same for preventing or treating metabolic diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/161,094 Continuation US10537559B2 (en) | 2015-08-17 | 2018-10-16 | Isonitramine compound and composition containing same for preventing or treating metabolic diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180244624A1 true US20180244624A1 (en) | 2018-08-30 |
Family
ID=58315965
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/752,592 Abandoned US20180244624A1 (en) | 2015-08-17 | 2016-08-17 | Novel isonitramine compound and composition containing same for preventing or treating metabolic diseases |
US16/161,094 Active US10537559B2 (en) | 2015-08-17 | 2018-10-16 | Isonitramine compound and composition containing same for preventing or treating metabolic diseases |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/161,094 Active US10537559B2 (en) | 2015-08-17 | 2018-10-16 | Isonitramine compound and composition containing same for preventing or treating metabolic diseases |
Country Status (2)
Country | Link |
---|---|
US (2) | US20180244624A1 (en) |
KR (1) | KR101799793B1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8383660B2 (en) | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
KR101509055B1 (en) | 2012-11-19 | 2015-04-08 | 대한민국 | Composition for preventing and curing obesity and lipid metabolism comprising ginseng extract |
-
2016
- 2016-08-17 KR KR1020160104145A patent/KR101799793B1/en active IP Right Grant
- 2016-08-17 US US15/752,592 patent/US20180244624A1/en not_active Abandoned
-
2018
- 2018-10-16 US US16/161,094 patent/US10537559B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20170021214A (en) | 2017-02-27 |
US10537559B2 (en) | 2020-01-21 |
US20190209534A1 (en) | 2019-07-11 |
KR101799793B1 (en) | 2017-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100972952B1 (en) | Agent for improving insulin resistance | |
KR101213825B1 (en) | Composition for the prevention and treatment of fatty liver diseases containing serine as an active ingredient | |
US10537559B2 (en) | Isonitramine compound and composition containing same for preventing or treating metabolic diseases | |
US20190070140A1 (en) | Composition comprising protectin dx as active ingredient for preventing or treating hyperlipidemia or fatty liver disease | |
US20120088840A1 (en) | Novel use of panduratin derivative or boesenbergia pandurata extract | |
JP2012072136A (en) | Composition for promoting intracellular metabolism, and pharmaceutical preparation for preventing and/or treating saccharometabolism or lipid metabolism disease, functional food, and health food containing the composition | |
KR101232872B1 (en) | Pharmaceutical composition for preventing and treating obesity comprising sphingosine-1-phosphate | |
EP3991728A1 (en) | Hepatic fibrosis-inhibiting agent and brown fat cell-activating agent containing taxifolin | |
KR20200056367A (en) | Composition for preventing, treating or improving obesity comprising Eupatilin as an active ingredient | |
KR101200671B1 (en) | Preventing and treating composition for obesity comprising polygammaglutamic acid | |
KR100842054B1 (en) | Composition containing extracts of Glycyrrhizin Radix Praepara or compounds isolated therefrom for the Blood Glucose-Lowering effect | |
KR101711072B1 (en) | Pharmaceutical composition comprising inhibitors of Fyn kinase for preventing or treating metabolic disease | |
US10426769B2 (en) | Pharmaceutical composition for preventing and treating obesity or liver diseases, containg TLR7 agonist | |
KR20190135378A (en) | Composition for preventing, treating, or improving obesity comprising the peptides derived from LGI3 as an active ingredients | |
JP5864003B1 (en) | Novel Rakan fruit extract composition having lipid accumulation inhibitory effect | |
US20230106742A1 (en) | Composition for inducing browning, containing milk exosomes | |
KR102009219B1 (en) | A composition for preventing or improving obesity or obesity-related disease comprising gentiopicroside | |
KR20120032372A (en) | Preventing and treating composition for obesity comprising dimethyl fumarate or its salts as an active ingredient | |
KR20230039352A (en) | Composition for preventing or treating cardiovascular disease comprising rosmarinic acid as an active ingredient | |
JP6533412B2 (en) | FoxO3a phosphorylation inhibition reagent | |
KR101848285B1 (en) | Composition comprising rhamnoarabinogalacturonan from mulberry fruit Oddi (Morous alba L.) as active ingredient for preventing or treating of obesity | |
KR101239055B1 (en) | Preventing and treating composition for obesity comprising zerumbone or its salts as an active ingredient | |
KR20210127655A (en) | Composition for preventing or treating obesity comprising Grateloupia elliptica | |
KR20240065851A (en) | Composition for the prevention and treatment of obesity comprising extract of fermented salicornia herbacea l. and extract of fermented artemisia annua l. | |
US20100125103A1 (en) | Composition for the treatment of diabetes and metabolic syndrome containing obovatol and its synthesized derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, HYO-JONG;PARK, YOHAN;PARK, HYEUNG-GEUN;SIGNING DATES FROM 20180214 TO 20180219;REEL/FRAME:045638/0556 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |